Latest On Novartis AG (NVSEF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-03-07 04:57 EST | Dividend | A dividend of $3.3 has been announced on Jan 31, 2024. It will be paid Mar 11, 2024 with an ex-dividend date of Mar 7, 2024. | Neutral |  |
| 2023-03-31 12:53 EST | News | Novartis reports mixed Q4 earnings, continue to grow with further core margin expansion; initiates FY23 guidance | N/A | |
| 2023-03-09 04:56 EST | Dividend | A dividend of $3.2 has been announced on Feb 1, 2023. It will be paid Mar 13, 2023 with an ex-dividend date of Mar 9, 2023. | Neutral | |
| 2022-03-08 04:56 EST | Dividend | A dividend of $3.1 has been announced on Feb 2, 2022. It will be paid Mar 10, 2022 with an ex-dividend date of Mar 8, 2022. | Neutral | |
| 2022-02-04 12:56 EST | News | Novartis (NVS) R&D Day - Slideshow | N/A | |
| 2021-12-23 03:28 EST | News | Novartis AG 2021 Q3 - Results - Earnings Call Presentation | N/A | |
| 2021-03-04 05:04 EST | Dividend | A dividend of $3 has been announced on Feb 3, 2021. It will be paid Mar 8, 2021 with an ex-dividend date of Mar 4, 2021. | Neutral | |
| 2021-01-28 05:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-26 22:13 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:24 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-02 05:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-26 14:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-09-17 06:45 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-14 10:40 EST | Financials | Company financials have been released. | Neutral | |
| 2020-08-06 10:01 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 18:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-30 06:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-29 22:32 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 22:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-27 14:16 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-23 19:00 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-09 10:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-07-01 18:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-19 14:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-14 06:12 EST | Financials | Company financials have been released. | Neutral | |
| 2020-06-12 07:46 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-27 06:49 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-21 02:22 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-06 06:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-05-01 02:04 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-28 16:08 EST | News | Novartis AG 2020 Q1 - Results - Earnings Call Presentation | N/A | |
| 2020-04-28 16:08 EST | News | Caution For Novartis, Rough Road Ahead, Sell | N/A | |
| 2020-04-28 16:07 EST | News | Novartis AG (NVS) CEO Vasant Narasimhan on Q1 2020 Results - Earnings Call Transcript | N/A | |
| 2020-04-26 09:50 EST | Financials | Company financials have been released. | Neutral | |
| 2020-04-24 03:23 EST | News | During These Tumultuous Times, Novartis Still Carries Quality Dividend Coverage | N/A | |
| 2020-04-03 22:23 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-25 21:56 EST | Financials | Company financials have been released. | Neutral | |
| 2020-03-03 04:57 EST | Dividend | A dividend of $2.95 has been announced on Jan 29, 2020. It will be paid Mar 5, 2020 with an ex-dividend date of Mar 3, 2020. | Neutral | |
| 2020-02-28 05:29 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-27 23:33 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-22 01:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-21 00:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-18 00:54 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-13 01:09 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-08 00:44 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-07 01:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-02-01 01:11 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-30 20:30 EST | Financials | Company financials have been released. | Neutral | |
| 2020-01-29 01:10 EST | Financials | Company financials have been released. | Neutral | |
About Novartis AG (NVSEF):
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
General
- Name Novartis AG
- Symbol NVSEF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 105,794
- Last Split Factor40:1
- Last Split Date2001-05-07
- Fiscal Year EndDecember
- Web URLhttp://www.novartis.com
View More
Valuation
- Trailing PE 23.8
- Forward PE 13.35
- Price/Sales (Trailing 12 Mt.) 3.92
- Price/Book (Most Recent Quarter) 3.4
- Enterprise Value Revenue 4.27
- Enterprise Value EBITDA 12.39
View More
Financials
- Most Recent Quarter 2020-12-31
- Profit Margin 16%
- Operating Margin 24%
- Return on Assets 6%
- Return on Equity 14%
- Revenue 49.76 billion
- Earnings Per Share $3.52
- Revenue Per Share $21.85
- Gross Profit 35.36 billion
- Quarterly Earnings Growth 1.9%
View More
ESG Rating
Highlights
- Market Capitalization 189.41 billion
- EBITDA 17.27 billion
- PE Ratio 14.01
- PEG Ratio 2.17
- Book Value Per Share $25.08
View More
Share Statistics
- Shares Outstanding 2.26 billion
- Shares Float 2.11 billion
- % Held by Insiders 584%
- % Held by Institutions 32.73%
View More
Technicals
- Beta 0.48
- 52 Week High $93.66
- 52 Week Low $67.92
- 50 Day Moving Average 88.09
- 200 Day Moving Average 88.54
View More
Dividends
- Forward Annual Dividend Rate $3.22
- Forward Annual Dividend Yield 3.77%
- Payout Ratio 94%
- Dividend Date 2018-03-08
- ExDividend Date 2021-03-04
- Dividend Per Share $3.4
- Dividend Yield 0%
View More
Novartis AG (NVSEF) Dividend Calendar:
NVSEF's last dividend payment was made to shareholders on March 8, 2018.
Novartis AG pays out 94% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Novartis AG (NVSEF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $13.03 billion | $0.92 | ||
| 2020-09-30 | 2020-12-31 | $12.54 billion | $0.92 | $1.45 | -36.48% |
| 2020-06-30 | 2020-09-30 | $11.62 billion | $0.84 | $1.32 | -36.36% |
| 2020-03-31 | 2020-06-30 | $12.71 billion | $0.81 | $1.39 | -41.73% |
| 2019-12-31 | 2020-03-31 | $12.72 billion | $0.95 | $1.30 | -26.92% |
| 2019-09-30 | 2019-12-31 | $12.48 billion | $0.49 | $1.34 | -63.34% |
| 2019-06-30 | 2019-09-30 | $12.02 billion | $0.89 | $1.22 | -27.05% |
| 2019-03-31 | 2019-06-30 | $11.46 billion | $0.90 | $1.15 | -21.74% |
| 2018-12-31 | 2019-03-31 | $13.66 billion | $0.80 | $1.28 | -37.5% |
| 2018-09-30 | 2018-12-31 | $11.78 million | $0.52 | $1.30 | -60.02% |
| 2018-06-30 | 2018-09-30 | $12.02 million | $0.80 | $1.27 | -37.01% |
| 2018-03-31 | 2018-06-30 | $12.93 billion | $3.29 | $1.27 | 159.06% |
| 2017-12-31 | 2018-03-31 | $13.16 billion | $0.84 | $1.18 | -28.81% |
| 2017-09-30 | 2017-12-31 | $12.69 billion | $0.84 | $1.25 | -32.47% |
| 2017-06-30 | 2017-09-30 | $12.49 billion | $0.88 | $1.19 | -26.05% |
| 2017-03-31 | 2017-06-30 | $11.79 billion | $0.83 | $1.12 | -25.89% |
| 2016-12-31 | 2017-03-31 | $0.70 | $1.11 | -36.94% | |
| 2016-09-30 | 2016-12-31 | $0.40 | $1.19 | -66.49% | |
| 2016-06-30 | 2016-09-30 | $0.81 | $1.18 | -31.36% | |
| 2016-03-31 | 2016-06-30 | $0.75 | $1.13 | -33.63% | |
| 2015-12-31 | 2016-03-31 | $0.84 | $1.20 | -30% | |
| 2015-09-30 | 2015-12-31 | $0.44 | $1.28 | -65.81% | |
| 2015-06-30 | 2015-09-30 | $0.74 | $1.29 | -42.64% | |
| 2015-03-31 | 2015-06-30 | $0.76 | $1.14 | -33.33% | |
| 2014-12-31 | 2015-03-31 | $0.94 | $1.19 | -21.01% | |
| 2014-09-30 | 2014-12-31 | $0.99 | $1.31 | -24.19% | |
| 2014-06-30 | 2014-09-30 | $1.25 | |||
| 2014-03-31 | 2014-06-30 | $1.09 | |||
| 2013-12-31 | 2014-03-31 | $0.97 | |||
| 2013-09-30 | 2013-12-31 | $0.80 | |||
| 2013-06-30 | 2013-09-30 | $0.86 | |||
| 2013-03-31 | 2013-06-30 | $1.03 | |||
| 2012-12-31 | 2013-03-31 | $1.02 | |||
| 2012-09-30 | 2012-12-31 | $0.81 | |||
| 2012-06-30 | 2012-09-30 | $0.98 | |||
| 2012-03-31 | 2012-06-30 | $1.09 | |||
| 2011-12-31 | 2012-03-31 | $0.92 | |||
| 2011-09-30 | 2011-12-31 | $0.49 | |||
| 2011-06-30 | 2011-09-30 | $1.01 | |||
| 2011-03-31 | 2011-06-30 | $1.11 | |||
| 2010-12-31 | 2011-03-31 | $1.20 | |||
| 2010-09-30 | 2010-12-31 | $0.94 | |||
| 2010-06-30 | 2010-06-30 | $1.05 | |||
| 2010-03-31 | 2010-03-31 | $1.28 | |||
| 2009-12-31 | 2009-12-31 | $1.01 | |||
| 2009-09-30 | 2009-09-30 | $0.92 | |||
| 2009-06-30 | 2009-06-30 | $0.89 | |||
| 2009-03-31 | 2009-03-31 | $0.86 | |||
| 2008-12-31 | 2008-12-31 | $0.67 | |||
| 2008-09-30 | 2008-09-30 | $0.92 | |||
| 2008-06-30 | 2008-06-30 | $0.98 | |||
| 2008-03-31 | 2008-03-31 | $1.02 | |||
| 2007-12-31 | 2007-12-31 | $0.40 | |||
| 2007-09-30 | 2007-09-30 | $2.96 | |||
| 2007-06-30 | 2007-06-30 | $0.85 | |||
| 2007-03-31 | 2007-03-31 | $0.92 | |||
| 2006-12-31 | 2006-12-31 | $0.70 | |||
| 2006-09-30 | 2006-09-30 | $0.79 | |||
| 2006-06-30 | 2006-06-30 | $0.72 | |||
| 2006-03-31 | 2006-03-31 | $0.83 | |||
| 2005-12-31 | 2005-12-31 | $0.58 | |||
| 2005-09-30 | 2005-09-30 | $0.71 | |||
| 2005-06-30 | 2005-06-30 | $0.70 | |||
| 2005-03-31 | 2005-03-31 | $0.64 | |||
| 2004-12-31 | 2004-12-31 | $0.56 | |||
| 2004-09-30 | 2004-09-30 | $0.63 | |||
| 2004-06-30 | 2004-06-30 | $0.63 | |||
| 2004-03-31 | 2004-03-31 | $0.52 | |||
| 2003-12-31 | 2003-12-31 | $0.54 | |||
| 2003-09-30 | 2003-09-30 | $0.51 |
Novartis AG (NVSEF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | 2.33 billion | 2.15 billion | 2.44 billion | 2.06 billion | 2.21 billion |
| Income Before Tax | 2.56 billion | 2.41 billion | 2.29 billion | 2.62 billion | 1.76 billion |
| Selling General Administrative | 3.92 billion | 3.42 billion | 3.37 billion | 3.49 billion | 3.92 billion |
| Gross Profit | 8.81 billion | 8.79 billion | 8.19 billion | 8.99 billion | 8.82 billion |
| Ebit | 4.43 billion | 4.35 billion | 4.21 billion | 4.27 billion | 2.58 billion |
| Operating Income | 2.64 billion | 2.41 billion | 2.35 billion | 2.74 billion | 2.58 billion |
| Income Tax Expense | 460 million | 478 million | 421 million | 448 million | 630 million |
| Total Revenue | 13.03 billion | 12.54 billion | 11.62 billion | 12.71 billion | 12.72 billion |
| Cost of Revenue | 4.22 billion | 3.75 billion | 3.43 billion | 3.72 billion | 3.9 billion |
| Total Other Income Expense Net | 141 million | 226 million | 183 million | 123 million | -825 million |
| Net Income From Continuing Operations | 2.1 billion | 1.93 billion | 1.87 billion | 2.17 billion | 1.13 billion |
| Net Income Applicable to Common Shares | 2.09 billion | 1.94 billion | 1.87 billion | 2.18 billion | 1.13 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | -2.05 billion | -425 million | -10.14 billion | 356 million | 493 million |
| Change to Liabilities | N/A | N/A | N/A | 553 million | N/A |
| Total Cash Flow from Investing Activities | -2.05 billion | -425 million | -10.14 billion | 318 million | -3.4 billion |
| Net Borrowings | 2.82 billion | -2.25 billion | 7.53 billion | -1.15 billion | 238 million |
| Total Cash Flow from Financial Activities | 1.91 billion | -2.17 billion | 1.03 billion | -1.2 billion | -2.71 billion |
| Change to Operating Activities | -1 billion | 230 million | -2.53 billion | 1.4 billion | 545 million |
| Change in Cash | 3.08 billion | 1.39 billion | -6.58 billion | 2.73 billion | -1.61 billion |
| Total Cash from Operating Activities | 3.16 billion | 3.96 billion | 2.53 billion | 3.54 billion | 4.56 billion |
| Depreciation | 1.73 billion | 1.7 billion | 1.41 billion | 1.24 billion | 1.25 billion |
| Other Cash Flow from Investing Activities | -26 million | -98 million | -55 million | -84 million | -6 million |
| Change to Inventory | N/A | N/A | N/A | -382 million | N/A |
| Change to Account Receivables | N/A | N/A | N/A | -980 million | N/A |
| Other Cash Flow from Financing Activities | 8 million | 39 million | -207 million | -42 million | -16 million |
| Change to Net Income | 978 million | 661 million | 1.55 billion | 583 million | 724 million |
| Capital Expenditures | 627 million | 452 million | 480 million | 461 million | 360 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | 75.39 billion | 75.12 billion | 69.88 billion | 72.12 billion | 62.82 billion |
| Total Stockholder Equity | 56.6 billion | 54.48 billion | 53.81 billion | 50.9 billion | 55.47 billion |
| Other Current Liabilities | 17.59 billion | 17.14 billion | N/A | N/A | 10.38 billion |
| Total Assets | 132.06 billion | 129.68 billion | 123.76 billion | 123.1 billion | 118.37 billion |
| Common Stock | 913 million | 913 million | 913 million | 936 million | 936 million |
| Other Current Assets | 2.52 billion | 2.67 billion | 2.73 billion | 2.93 billion | 1.05 billion |
| Retained Earnings | N/A | 57.4 billion | 57.5 billion | 55.36 billion | 59.28 billion |
| Other Liabilities | 14.36 billion | 15.11 billion | 14.84 billion | 15.34 billion | 12.5 billion |
| Other Assets | 9.11 billion | 9.8 billion | 9.91 billion | 9.53 billion | 14.8 billion |
| Cash | 9.66 billion | 8.99 billion | 5.92 billion | 4.53 billion | 11.11 billion |
| Total Current Liabilities | 33.06 billion | 31.84 billion | 29.38 billion | 31.29 billion | 28.26 billion |
| Other Stockholder Equity | 55.74 billion | -3.79 billion | -4.56 billion | -5.32 billion | -4.66 billion |
| Property, Plant & Equipment | 13.94 billion | 13.34 billion | 13.6 billion | 13.56 billion | 13.75 billion |
| Total Current Assets | 29.67 billion | 28.97 billion | 23.88 billion | 23.1 billion | 29.5 billion |
| Long Term Investments | 11.7 billion | 11.6 billion | 11.05 billion | 10.52 billion | 10.43 billion |
| Net Tangible Assets | -10.21 billion | -11.93 billion | -11.96 billion | -15.49 billion | 5.59 billion |
| Short Term Investments | 1.91 billion | 1.88 billion | 376 million | 445 million | 232 million |
| Long Term Debt | 26.26 billion | 26.5 billion | 23.96 billion | 23.8 billion | 20.35 billion |
| Inventory | 7.13 billion | 7.14 billion | 6.9 billion | 6.4 billion | 5.98 billion |
| Accounts Payable | 5.4 billion | 4.71 billion | 4.82 billion | 4.83 billion | 5.42 billion |
Novartis AG (NVSEF) Chart:
Novartis AG (NVSEF) News:
Below you will find a list of latest news for Novartis AG (NVSEF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Novartis AG (NVSEF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Novartis AG (NVSEF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|